Cargando…

Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome

We recently showed that myelin basic protein (MBP) is hydrolyzed by 26S proteasome without ubiquitination. The previously suggested concept of charge-mediated interaction between MBP and the proteasome led us to attempt to compensate or mimic its positive charge to inhibit proteasomal degradation. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuzina, Ekaterina, Kudriaeva, Anna, Smirnov, Ivan, Dubina, Michael V., Gabibov, Alexander, Belogurov, Alexey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172982/ https://www.ncbi.nlm.nih.gov/pubmed/25276831 http://dx.doi.org/10.1155/2014/926394

Ejemplares similares

Multiple Sclerosis Autoantigen Myelin Basic Protein Escapes Control by Ubiquitination during Proteasomal Degradation
por: Belogurov, Alexey, et al.
Publicado: (2014)

Analysis of Myelin Basic Protein Fragmentation by Proteasome
por: Bacheva, A. V., et al.
Publicado: (2009)

Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity
por: Belogurov, Alexey, et al.
Publicado: (2015)

Autoantigen microarrays reveal myelin basic protein autoantibodies in morphea
por: Zhu, Jane L., et al.
Publicado: (2022)

Comprehensive Atlas of the Myelin Basic Protein Interaction Landscape
por: Smirnova, Evgeniya V., et al.
Publicado: (2021)

The nanny and the iceberg /
por: Dorfman, Ariel
Publicado: (1999)

Identification of Myelin Basic Protein Proximity Interactome Using TurboID Labeling Proteomics
por: Smirnova, Evgeniya V., et al.
Publicado: (2023)

Myelin Basic Protein Fragmentation by Engineered Human Proteasomes with Different Catalytic Phenotypes Revealed Direct Peptide Ligands of MS-Associated and Protective HLA Class I Molecules
por: Saratov, George A., et al.
Publicado: (2023)

Passive Smoking and the Nanny State
Publicado: (1998)

Synthetic Cationic Autoantigen Mimics Glatiramer Acetate Persistence at the Site of Injection and Is Efficacious Against Experimental Autoimmune Encephalomyelitis
por: Song, Jimmy Y., et al.
Publicado: (2021)

Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)

The Transcriptome of Type I Murine Astrocytes under Interferon-Gamma Exposure and Remyelination Stimulus
por: Kudriaeva, Anna, et al.
Publicado: (2017)

Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients
por: Lomakin, Yakov, et al.
Publicado: (2016)

Beyond the ‘nanny state’: Stewardship and public health
por: Calman, K.
Publicado: (2009)

Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007)

Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone(®)
por: Lipsky, Peter, et al.
Publicado: (2021)

Multiple discrete encephalitogenic epitopes of the autoantigen myelin basic protein include a determinant for I-E class II-restricted T cells
Publicado: (1988)

The role of glatiramer acetate in the early treatment of multiple sclerosis
por: Brandes, David W
Publicado: (2010)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Glatiramer Acetate-associated Refractory Immune Thrombocytopenic Purpura
por: Sagy, Iftach, et al.
Publicado: (2016)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
por: Komlosh, Arthur, et al.
Publicado: (2019)

Bullous pemphigoid as an injection site reaction of glatiramer acetate
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2019)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
por: Kasindi, Arielle, et al.
Publicado: (2022)

An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate
por: Erzina, Dina, et al.
Publicado: (2021)

CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study
por: Belogurov, Alexey, et al.
Publicado: (2016)

Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience
por: de Oliveira, Tatiana de Melo Gomes, et al.
Publicado: (2008)

Glatiramer acetate desensitisation in multiple sclerosis patients - the case report
por: Novotna, Bronislava, et al.
Publicado: (2014)

Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
por: Izquierdo, Guillermo, et al.
Publicado: (2015)

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial
por: Arnold, Douglas L., et al.
Publicado: (2013)

Metabolic response to glatiramer acetate therapy in multiple sclerosis patients
por: De Riccardis, Lidia, et al.
Publicado: (2016)

Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
por: D’Alessandro, Josephine, et al.
Publicado: (2017)

Process signatures in glatiramer acetate synthesis: structural and functional relationships
por: Campos-García, Víctor R., et al.
Publicado: (2017)

Embolia Cutis Medicamentosa after Subcutaneous Injection with Glatiramer Acetate
por: Vlahova, Lyubomira, et al.
Publicado: (2021)

Linear epitopes of two different autoantigens (La/SSB and myelin basic protein) with a high degree of molecular similarity cause different humoral responses
por: Terzoglou, A, et al.
Publicado: (2003)

Adhesion Process of Biomimetic Myelin Membranes Triggered by Myelin Basic Protein
por: Krugmann, Benjamin, et al.
Publicado: (2021)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
por: Fernández, Oscar
Publicado: (2012)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2009)

Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic
por: Towfic, Fadi, et al.
Publicado: (2014)

Glatiramer acetate treatment negatively regulates type I interferon signaling
Publicado: (2015)

Restoration of Axon Conduction and Motor Deficits by Therapeutic Treatment with Glatiramer Acetate
por: Moore, Spencer, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kutj0be6ulktu2sckb5lgltsr8